It's a big morning for much-maligned trans fats. The New York City Board of Health meets today to decide whether to ban the artery-clogging oils from all the city's eateries. Ashley Milne-Tyte reports.
An influential doctor's association has issued a call to ban all questionable advertising targeted at children. But will it translate into real legislative action? Lisa Napoli reports.
Pfizer halted development of its new cholesterol drug following unexpected deaths during test trials. It's a huge blow to the drugmaker, which needs a blockbuster with Lipitor's patent set to expire in 5 years. Helen Palmer reports.
Commentator and economist Susan Lee says government interference in the fat market makes sense but wonders, exactly how much are taxpayers willing to spend? A new study provides a surprising answer.
Drug giant Pfizer halted development of its most promising experimental drug after more than 80 people died during test trials. This is a major setback for the company, Stacey Vanek-Smith reports.
The nation's largest drugstore chains say they're working to improve patient privacy after an investigative reporter easily found sensitive information about their customers.
Former president Bill Clinton announced that his negotiated significantly cheaper HIV treatment for children in India, home to the world's largest HIV-positive population. Miranda Kennedy reports.
Democrats want to use Medicare to negotiate lower drug prices for seniors. Republicans and drug companies say it'll amount to government price controls. Commentator Robert Reich says that's absurd.
Pfizer has announced that it will slash 20 percent of its workforce. The company's plagued by an industry-wide problem, as drug reps find it harder and harder to get face time with doctors. Helen Palmer reports.
